CLYM
Climb Bio Inc
NASDAQ: CLYM · HEALTHCARE · BIOTECHNOLOGY
$8.88
+1.14% today
Updated 2026-04-30
Market cap
$436.60M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.88
Dividend yield
—
52W range
$1 – $10
Volume
0.6M
Climb Bio Inc (CLYM) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | $97000.00 |
| Gross profit | — | — | — | — | — | — | $-97000.00 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $4.02M | $9.34M | $23.32M | $26.21M | $15.41M | $14.34M | $46.62M |
| SG&A | $677000.00 | $2.42M | $12.35M | $18.92M | $24.86M | $16.02M | $21.17M |
| Operating income | $-7.45M | $-20.93M | $-35.67M | $-45.13M | $-40.27M | $-82.02M | $-67.88M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-4.70M | $-11.77M | $-35.67M | $-45.13M | $-40.27M | $-30.36M | $-67.79M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-7.45M | $-20.93M | $-35.67M | $-45.13M | $-40.27M | $-82.02M | $-67.88M |
| Interest expense | — | — | — | — | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-6.55M | $-20.67M | $-47.48M | $-45.24M | $-35.12M | $-73.90M | $-59.85M |
| Net income growth (YoY) | — | -215.7% | -129.7% | +4.7% | +22.4% | -110.4% | +19.0% |
| Profit margin | — | — | — | — | — | — | — |